R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BiotechHKG: 9688

Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center

Biocytogen PharmaceuticalsBiotech

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

AICathay Biotech

MoleculeMind Raises Over RMB 100 Million for AI Protein Design Platform

CancerPrecision medicine

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Show More